Mirum Pharmaceuticals (MIRM) Price & Analysis

Compare

692 Followers

MIRM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$36.86 - $54.78

Previous CloseN/A

Volume92.82K

Average Volume (3M)377.38K

Market Cap

$2.57B

Enterprise Value$0.00

Total Cash (Recent Filing)$277.67M

Total Debt (Recent Filing)$317.16M

Price to Earnings (P/E)―

Beta0.69

Next Earnings

Nov 12, 2025

EPS Estimate

-0.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding49,534,710

10 Day Avg. Volume326,757

30 Day Avg. Volume377,384

Financial Highlights & Ratios

PEG Ratio0.42

Price to Book (P/B)8.71

Price to Sales (P/S)5.83

P/FCF Ratio210.57

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$78.00

Price Target Upside30.39% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

International ExpansionMirum’s commercial partner in Japan, Takeda, secured reimbursement for LIVMARLI and began sales, boosting international presence.

Product DevelopmentThe recently approved Livmarli tablet formulation is seen as potentially driving new patient and switch scenarios by increasing flexibility.

Revenue GrowthLIVMARLI commercial momentum drives up 2025 revenue guidance.

Bears Say

Adverse EventsDiarrhea was the most commonly reported adverse event associated with volixibat.

Competitive LandscapeLivmarli's oral tablet formulation could narrow the competitive gap in PFIC new patient starts.

Mirum Pharmaceuticals News

Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond James

Raymond James raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $82 from $77 and keeps a...

1d ago

MIRM

Mirum Pharmaceuticals price target raised to $81 from $79 at Citizens JMP

Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $81 from $79...

1d ago

MIRM

Mirum Pharmaceuticals price target raised to $80 from $73 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $80 from $73 and keeps a...

1d ago

MIRM

Mirum Pharmaceuticals reports Q2 EPS (12c), consensus (33c)

Reports Q2 revenue $128M, consensus $108.1M. “Our second quarter results once again underscore the strength of our commercial...

2d ago

MIRM

Mirum Pharmaceuticals price target raised to $76 from $68 at Evercore ISI

Evercore ISI raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $76 from $68 and keeps an...

28d ago

MIRM

Buy Rating Affirmed for Mirum Pharmaceuticals Amid Strong Financial Performance and Growth Potential

Mirum Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst on August 6. Analyst Mani...

7h ago

MIRM

Mirum Pharmaceuticals Reports Strong Q2 Growth and Raises Guidance

Mirum Pharmaceuticals (($MIRM)) has held its Q2 earnings call. Read on for the main highlights of the call....

16h ago

MIRM

Strong Commercial Performance and Strategic Initiatives Drive Buy Rating for Mirum Pharmaceuticals

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Mirum Pharmaceuticals. The associated price target...

1d ago

MIRM

Mirum Pharmaceuticals Reports Strong Q2 2025 Growth

Mirum Pharmaceuticals ( ($MIRM) ) has released its Q2 earnings. Here is a breakdown of the information Mirum...

2d ago

MIRM

Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment

Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical study. The clinical study titled ‘A Randomized, Double-Blind,...

8d ago

MIRM

Mirum Pharmaceuticals Advances Phase 3 Study on Maralixibat for Cholestatic Pruritus

Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical study. Mirum Pharmaceuticals is conducting a Phase 3...

22d ago

MIRM

Mirum Pharmaceuticals’ Volixibat Study: A Potential Game-Changer for PBC Treatment

Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical study. Mirum Pharmaceuticals is conducting a study titled...

1M ago

MIRM

Mirum Pharmaceuticals Holds 2025 Annual Stockholders Meeting

An announcement from Mirum Pharmaceuticals ( ($MIRM) ) is now available. On May 29, 2025, Mirum Pharmaceuticals held...

2M ago

MIRM

Mirum Pharmaceuticals appoints Doug Sheehy as Chief Legal Officer

Mirum Pharmaceuticals (MIRM) announced the appointment of Doug Sheehy as Chief Legal Officer. Sheehy was most recently Chief...

3M ago

MIRM

MIRM FAQ

What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?

Mirum Pharmaceuticals Inc lowest stock price was $36.86 and its highest was $54.78 in the past 12 months.

What is Mirum Pharmaceuticals Inc’s market cap?

Mirum Pharmaceuticals Inc’s market cap is $2.57B.

When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?

Mirum Pharmaceuticals Inc’s upcoming earnings report date is Nov 12, 2025 which is in 96 days.

How were Mirum Pharmaceuticals Inc’s earnings last quarter?

Mirum Pharmaceuticals Inc released its earnings results on Aug 06, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.326 by $0.206.

Is Mirum Pharmaceuticals Inc overvalued?

According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mirum Pharmaceuticals Inc pay dividends?

Mirum Pharmaceuticals Inc does not currently pay dividends.

What is Mirum Pharmaceuticals Inc’s EPS estimate?

Mirum Pharmaceuticals Inc’s EPS estimate is -0.18.

How many shares outstanding does Mirum Pharmaceuticals Inc have?

Mirum Pharmaceuticals Inc has 49,534,710 shares outstanding.

What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?

Mirum Pharmaceuticals Inc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.326. Following the earnings report the stock price went up 12.043%.

Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in MIRM

Mirum Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-24.19%

Trailing 12-Months

Asset Growth

5.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

Mirum Pharmaceuticals (MIRM) Earnings & Revenues

Historic Earnings Reports

MIRM Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant revenue growth, strong performance of key products, and multiple regulatory approvals, indicating positive business momentum. However, high operating expenses and non-cash charges were noted as challenges.View all MIRM earnings summaries

MIRM Stock 12 Month Forecast

Average Price Target

$78.00

▲(30.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","90":"$90","39.75":"$39.8","56.5":"$56.5","73.25":"$73.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$89.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$66.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,39.75,56.5,73.25,90],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.39,51.51384615384615,54.637692307692305,57.761538461538464,60.885384615384616,64.00923076923077,67.13307692307693,70.25692307692307,73.38076923076923,76.50461538461539,79.62846153846154,82.7523076923077,85.87615384615384,{"y":89,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.39,50.667692307692306,52.94538461538462,55.223076923076924,57.50076923076923,59.77846153846154,62.05615384615385,64.33384615384615,66.61153846153846,68.88923076923078,71.16692307692307,73.44461538461539,75.7223076923077,{"y":78,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.39,49.744615384615386,51.09923076923077,52.45384615384616,53.808461538461536,55.16307692307692,56.51769230769231,57.87230769230769,59.22692307692308,60.58153846153846,61.93615384615384,63.29076923076923,64.64538461538461,{"y":66,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.03,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.16,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.13,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.42,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.39,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >